Compare HLIO & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLIO | NBTX |
|---|---|---|
| Founded | 1970 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 1996 | 2018 |
| Metric | HLIO | NBTX |
|---|---|---|
| Price | $48.25 | $32.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $80.50 | $54.24 |
| AVG Volume (30 Days) | ★ 464.2K | 136.4K |
| Earning Date | 11-05-2026 | 09-24-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | ★ 23.93 | N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $200,727,000.00 | N/A |
| Revenue This Year | $6.99 | N/A |
| Revenue Next Year | $4.59 | $50.69 |
| P/E Ratio | $26.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $46.95 | $19.14 |
| 52 Week High | $95.05 | $57.14 |
| Indicator | HLIO | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 22.86 | 58.56 |
| Support Level | N/A | $30.73 |
| Resistance Level | $70.81 | $35.17 |
| Average True Range (ATR) | 2.81 | 1.87 |
| MACD | -2.04 | 0.53 |
| Stochastic Oscillator | 5.64 | 72.18 |
Helios Technologies Inc is an industrial technology company that develops, manufactures, and markets solutions for the hydraulics and electronics markets. It operates under two business segments: Hydraulics and Electronics. The Hydraulics segment designs and manufactures hydraulic components and systems used to transmit power and control force, speed, and motion. There are two categories based on Hydraulic system architecture: MCT and FCT. The Electronics segment provides complete, fully-tailored display and control solutions for engines, engine-driven equipment, specialty vehicles, therapy baths, and traditional and swim spas. The company generates the majority of its revenue from the Hydraulics segment. Geographically, the company generates key revenue from the Americas region.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.